I knew your list was not exactly high risk. I follow Nektar and think they have significant upside with much less risk than in the Exubera days. I think Chess has done a great job since taking over. I also think Elan has less risk than it used to.
BTW: Regarding risk, In spite of losing a huge amount of paper profits holding on too long, I have manged to sell enough times that I have earned a very nice profit investing in biotech over the years.
Market Data 
Markets 
AI
